China's Clover says its Covid-19 booster shot candidate lifts antibody against Omicron

BEIJING, June 27 (Reuters): China's Clover Biopharmaceuticals said on Monday a booster shot of its Covid-19 vaccine candidate significantly increased antibody response against the Omicron coronavirus variant from levels seen after two primary shots.

A third dose of its vaccine candidate SCB-2019 resulted in a 19-fold increase in neutralising antibody levels against the Omicron BA.2 subvariant from pre-booster levels, Clover said in a filing to the Hong Kong stock exchange.